Can-Fite BioPharma Ltd. CANF

Company Overview

Can-Fite BioPharma Ltd. is an Israel-based clinical-stage biotechnology company focused on developing small-molecule therapeutics that target the A3 adenosine receptor (A3AR) and related adenosine receptor pathways. The company operates within the biopharmaceutical and drug development industries, with a primary emphasis on inflammatory diseases, liver disorders, oncology, and metabolic conditions. Its lead drug candidates include Piclidenoson for psoriasis and other inflammatory conditions, Namodenoson for liver diseases and hepatocellular carcinoma, and CF602 for erectile dysfunction. The company’s revenue profile has historically been driven primarily by licensing agreements, collaboration arrangements, and capital market financing rather than commercialized product sales, as its therapeutic candidates remain in clinical development.

Can-Fite was founded in 1994 and is headquartered in Petah Tikva, Israel. The company was established around research conducted on adenosine receptor biology and has evolved into a clinical-stage biotechnology enterprise with multiple investigational compounds targeting diseases with significant unmet medical need. Can-Fite has positioned itself around the selective targeting of A3AR, which the company states is highly expressed in pathological inflammatory and cancer cells while demonstrating lower expression in normal tissues. This receptor-focused platform has formed the basis of its intellectual property portfolio and clinical development strategy.